Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients
A Single-Arm, Single-Center Exploratory Study of Amimestrocel Injection for the Prevention of Gastrointestinal Mucositis Induced by Conditioning Regimens Containing TBI and/or Melphalan
The First Affiliated Hospital of Soochow University
22 participants
Feb 15, 2026
INTERVENTIONAL
Conditions
Summary
This study aims to see if a single intravenous infusion of a cell therapy called Amimestrocel injection can help prevent severe mouth sores (oral mucositis) in patients receiving a stem cell transplant. Patients getting a stem cell transplant often receive strong chemotherapy (with radiation and/or a drug called melphalan) that can cause painful mouth and gut sores, making eating difficult and increasing infection risk. Amimestrocel injection is made from human umbilical cord cells that may help reduce inflammation and promote healing. About 22 adult patients scheduled for this type of transplant at one hospital in China will receive the infusion 1-2 days before their stem cell transplant. Researchers will closely check for mouth sores, pain, and side effects for the first 28 days, and continue safety monitoring for 100 days. The main goal is to see if the treatment lowers the rate of severe (Grade 3-4) mouth sores. The study will also track pain levels, need for pain medication, diarrhea, time for blood counts to recover, and overall safety.
Eligibility
Inclusion Criteria6
- Aged 18 to 65 years.
- Planned to undergo myeloablative allogeneic hematopoietic stem cell transplantation.
- The conditioning regimen must contain total body irradiation (TBI) and/or melphalan.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ function defined as:Left ventricular ejection fraction (LVEF) ≥ 50%.Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN).Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 60 mL/min.
- Voluntarily signs the informed consent form.
Exclusion Criteria7
- History of allergy to mesenchymal stem cells or any component of the Amimestrocel injection preparation.
- Presence of active, uncontrolled bacterial, fungal, or viral infection.
- History of other malignancies within the past 5 years, except for cured carcinoma in situ or basal cell skin cancer.
- Pregnant or lactating women, or those planning pregnancy during the study period.
- Previous receipt of any cell therapy product.
- Severe psychiatric disorder or cognitive impairment that would limit the ability to provide informed consent or comply with study procedures.
- Any condition that, in the investigator's judgment, makes the subject unsuitable for study participation.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Amimestrocel injection is an allogeneic (donor-derived), umbilical cord mesenchymal stem cell (UC-MSC) suspension for intravenous infusion. It is supplied as a cryopreserved cell suspension in a single-dose bag containing 6.0×10⁷ viable cells in 12 mL. For this study, a single bag is thawed and administered as a one-time intravenous infusion.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07400328